A new license to adapt EORTC questionnaires into electronic versions

As of 15 May 2021, the EORTC will introduce a new license for any Electronic Outcome Assessment (eCOA) provider or other entity (e.g. CRO or pharmaceutical company) adapting – or “migrating” – the EORTC Quality of Life Group questionnaires and modules into electronic versions (e-versions) and making these e-versions available for use in clinical trials or other studies. This license is subject to a royalty fee when the e-version(s) will be used in commercial trials or studies. When adapting the questionnaires into an in e-version for use in academic trials, the license will still be required, however no royalty fee will be charged.

There are two types of licenses:

  1. The “Study Solution” where a provider will adapt an EORTC questionnaire for a single study; or
  2. The “Library Solution” where a provider will create a “library” of e-versions of EORTC Quality of Life Group Questionnaire, available for use in clinical trials and studies.

For any further queries regarding these licensing solutions, their scope and fees, please contact EORTC at:

With this new license, the EORTC aims to improve the quality and consistency of the e-versions of its questionnaires.

We thank you for your understanding of this evolution of EORTC processes and we look forward to a continued collaboration.

Back to news list

Related News

  • EORTC Quality of Life Group celebrating 40 years

  • Results of two EORTC studies have been published in NEJM and the Lancet Oncology

  • Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous

  • New results, updates, and forthcoming EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer presented at ESMO 2022

  • Important new data from EORTC trials to be presented at ESMO 2022

  • EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds

  • EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

  • In Memoriam: Dr Martin Charles Mihm

  • The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation